Skip to main content

news

Shardul Amarchand Mangaldas & Co (SAM) has advised private equity major Advent International on the purchase of a 50.1 percent stake in India’s Suven Pharmaceuticals, with Cyril Amarchand Mangaldas (CAM) advising the sellers, the Jasti family.

According to Reuters, Advent is expected to make an additional open offer for up to 26 percent of the voting share capital held by public shareholders. Advent intends to explore merging Suven with its wholly owned Cohance Lifesciences to build a company that specializes in active pharmaceutical ingredients as well as contract development and manufacturing businesses, Reuters added.

 

The CAM team was led by partner Shishir Vayttaden, with support from partners Namrata Kolar, Biplab Lenin, and Avaantika Kakkar.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.